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Sirtuins are NAD+-dependent protein deacety-
lases and are emerging as molecular targets
for the development of pharmaceuticals to treat
human metabolic and neurological diseases
and cancer. To date, several sirtuin inhibitors
and activators have been identified, but the
structural mechanisms of how these com-
pounds modulate sirtuin activity have not yet
been determined. We identified suramin as a
compound that binds to human SIRT5 and
showed that it inhibits SIRT5 NAD+-dependent
deacetylase activity with an IC50 value of 22 mM.
To provide insights into how sirtuin function is
altered by inhibitors, we determined two crystal
structuresofSIRT5, one in complexwithADP-ri-
bose, the other bound to suramin. Our structural
studies provide a view of a synthetic inhibitory
compound in a sirtuin active site revealing that
suramin binds into the NAD+, the product, and
the substrate-binding site. Finally, our struc-
turesmay enable the rational designofmorepo-
tent inhibitors.
INTRODUCTION
Sirtuins belong to the class III histone deacetylases and are
NAD+-dependent hydrolases. They catalyze the deacety-
lation of acetylated lysine residues of histone substrates
and are also reported to act on nonhistone substrates
such as the cytoskeletal protein a-tubulin (North et al.,
2003), acetyl-CoA synthetase (Starai et al., 2002), and sev-
eral transcription factors like the p53 tumor suppressor
protein (Vaziri et al., 2001). Besides the deacetylation
reaction, some sirtuins have been shown to have ADP-
ribosyltransferase activity (Sauve and Schramm, 2004;
Liszt et al., 2005). Sirtuins are involved in various biological
processes, including development, heterochromatin for-
mation, gene silencing, DNA repair, genome stability,
metabolism, longevity, adipogenesis, and apoptosisStructure 15, 37(reviewed in Zhao and Marmorstein, 2006). Sirtuins link
aging, cancer, and diet and thus are potential molecular
targets for the development of pharmaceuticals to treat
human metabolic and neurological diseases and malig-
nancy (Hede, 2006).
Sirtuins are conserved from bacteria to eukaryotes and
are named according to the founding member yeast Sir2
(silent information regulator 2) (Gray and Ekstrom, 2001).
Humans have seven sirtuin genes termed SIRT1 to
SIRT7 that group into four classes (I–IV). Among them,
SIRT5 is a class III sirtuin and is phylogenetically closest
to prokaryotic sirtuins (Frye, 2000). In bacteria, which
typically lack histones, sirtuins control the enzyme that
converts acetate into acetyl-CoA, acetyl-CoA synthetase,
a key component of cellular respiration (Starai et al., 2002).
The biological function of human SIRT5 has not yet been
determined. However, the human SIRT5 gene is located in
chromosomal region 6p23, and it is most predominantly
expressed in brain, testis, heart muscle cells, and in
lymphoblasts (Mahlknecht et al., 2006; Michishita et al.,
2005). SIRT5 has detectable deacetylase activity (North
et al., 2005; Howitz and Zipkin, 2006), and, since it is local-
ized in mitochondria, it has been proposed that SIRT5 may
link metabolic and aging processes in humans (Michishita
et al., 2005).
In the past few years, several crystal structures of sirtuin
proteins have been reported, either uncomplexed (Finnin
et al., 2001; Zhao et al., 2003a; Avalos et al., 2004) or
bound to NAD+ analogs and/or acetyl-lysine peptide sub-
strates (Min et al., 2001; Chang et al., 2002; Zhao et al.,
2003b, 2004b, 2004a; Avalos et al., 2002, 2004, 2005;
Cosgrove et al., 2006; Hoff et al., 2006). These structures
provided important insights into the catalytic mechanism
of sirtuins, such as the mechanism by which NAD+ cleav-
age occurs (Zhao et al., 2004b; Hoff et al., 2006), the
mechanism for sirtuin inhibition by the reaction product
nicotinamide (Avalos et al., 2005), and how sirtuins
discriminate among different substrates (Zhao et al.,
2004a; Cosgrove et al., 2006).
Sirtuin activity can be modulated by potentially thera-
peutic small molecules (Grubisha et al., 2005; Howitz et al.,
2003; Porcu and Chiarugi, 2005). The sirtuin inhibitors, like
sirtinol and splitomicin, sensitize cells to p53-dependent7–389, March 2007 ª2007 Elsevier Ltd All rights reserved 377
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SIRT5 Crystal StructureFigure 1. Biophysical and Biochemical
Data for SIRT5
(A) ITC data for suramin binding to SIRT5. The
upper panel shows the sequential heat pulses
for suramin binding to SIRT5, and the lower
panel shows the integrated heat data, cor-
rected for the heat of dilution and fit to a single-
site binding model.
(B) SIRT5 has NAD+-nicotinamide exchange
activity in the presence of an acetylated sub-
strate. Enzyme plus either BSA () or acety-
lated BSA (+) was incubated with radioactive
nicotinamide (Nic). The appearance of radio-
active NAD+ is a sign of NAD+-nicotinamide
exchange activity. Lanes 1 and 2 (no enzyme);
lanes 3 and 4 (recombinant yeast Sir2); lanes
5–8 (SIRT5, with increasing enzyme concentra-
tions in lanes 6–8).
(C) Suramin inhibits SIRT5 NAD+-dependent
deacetylase activity with an IC50 of 22 mM.
Points are triplicates normalized to the ratio
of uninhibited/inhibited enzyme, with error
bars representing the standard deviation of
the mean.cell death and therefore resemble a new class of chemo-
therapeutics effective in cancer therapy. Sirtuin activators,
like resveratrol and quercetin, enhance stress resistance
and DNA repair and protect human cells from p53-depen-
dent apoptosis, thus extending life span (reviewed in
Porcu and Chiarugi, 2005; Guarente and Picard, 2005).
Despite this accumulated knowledge, the detailed struc-
tural and molecular mechanisms by which these com-
pounds alter sirtuin activity have not yet been determined.
To provide insights into the action of small-molecule mod-
ulators on sirtuin function, we report here two crystal
structures of human SIRT5, one in complex with ADP-ri-
bose, the other bound to suramin, a SIRT5 inhibitor we
identified by screening a library of small molecules. We
show that suramin inhibits sirtuin activity by binding into
the B- and C-pockets of the NAD+-binding site as well
as to the substrate-binding site. Finally, our structural
studies provide, to our knowledge, the first view of a syn-
thetic inhibitory compound in a sirtuin active site and may
enable the rational design of more potent inhibitors with
potential therapeutic applications.
RESULTS AND DISCUSSION
Identifying Suramin as aCompoundBinding to SIRT5
In a temperature-dependent aggregation-based screen-
ing of SIRT5 protein against a customized library of small
molecules (Vedadi et al., 2006), we found that suramin
(8,80-[carbonylbis [imino-3,1-phenylenecarbonylimino
(4-methyl-3,1-phenylene) carbonylimino]] bis-1,3,5-naph-
talenetrisulfonic acid) binds to human SIRT5 and stabilizes
its thermally induced aggregation by 30C (data not
shown). By using isothermal titration calorimetry, a binding
constant of 5.5 ± 0.1 mM was determined for suramin to
SIRT5 (Figure 1A).
Suramin was developed within the Bayer AG in 1916
and is used for the treatment of sleeping sickness and on-378 Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd Allchocerciasis, an infectious cause of blindness (Hawking,
1978). Suramin has antiapoptotic effects in the liver (Eich-
horst et al., 2004), and it has been studied for its potential
use as an anticancer agent and chemosensitizer in cancer
patients (Villalona-Calero et al., 2003).
SIRT5 Activity Assays
In order to explore how suramin modulates SIRT5 func-
tion, we tested SIRT5 activity in enzyme assays (Landry
and Sternglanz, 2003). We first showed that SIRT5 has
NAD+-nicotinamide exchange activity in the presence of
an acetylated substrate. Enzyme and acetylated BSA
were incubated with radioactive nicotinamide. NAD+ and
acetylated substrate reacted with SIRT5, and the subse-
quent enzyme-ADP ribose-like intermediate reacted with
exogenous labeled nicotinamide to form labeled NAD+
(Figure 1B). The reaction only occurred in the presence
of acetylated substrate, indicating that the hydrolysis of
the N-glycosidic bond between nicotinamide and ribose
only occurred in the presence of acetylated substrate.
Furthermore, SIRT5 had NAD+-dependent deacetylase
activity with chemically acetylated chicken histone as
substrate. SIRT5 displayed less activity toward chemically
acetylated BSA and monoacetylated H4 (K16 and K8). No
activity was observed with monoacetylated histone K5
and K12 histone H4 peptides (data not shown). To test
the effect and potency of suramin, we performed SIRT5
activity assays in the presence of the compound. Suramin
appeared to inhibit SIRT5 NAD+-dependent deacetylase
activity with an IC50 value of 22 mM (Figure 1C).
Previously performed activity assays of human SIRT5
showed that the enzyme has considerably lower deacety-
lase activity compared with human SIRT1, SIRT2, and
SIRT3, with chemically acetylated histone H4 peptide as
substrate (North et al., 2005; Heltweg et al., 2006). There-
fore, SIRT5 may preferentially recognize nonhistone sub-
strates. In fact, SIRT5 was shown to deacetylate p53rights reserved
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SIRT5 Crystal StructureK382 peptide (Howitz and Zipkin, 2006) and cytochrome
c, chemically acetylated with [3H] acetate (Solomon
et al., 2006), but SIRT5 was not capable of deacetylating
the mitochondrial acetyl-CoA synthetase (Schwer et al.,
2006; Hallows et al., 2006). The native acetylated sub-
strate of SIRT5, as well as its biological function, remains
unknown.
Past attempts to modulate sirtuin activity resulted in the
identification of a variety of compounds, most of them
displaying their effects at micromolar concentrations
(Grubisha et al., 2005; Howitz et al., 2003; Porcu and
Chiarugi, 2005). Here, we describe suramin as an inhibitor
for SIRT5. With an IC50 value of 22 mM, suramin has
a similar inhibitory effect on SIRT5 as it does for human
SIRT1 (IC50 of 2.6 mM) (Biomol International LP; http://
www.biomol.com/Online_Catalog/Online_Catalog/Products/
Product_Detail/38/?categoryId=16&productId=624&mid
=75). The potency of suramin is comparable to other inhib-
itors identified for sirtuin proteins. Sirtinol for example,
which is chemically similar to suramin, was shown to in-
hibit human SIRT2 with an IC50 of 38 mM (Grozinger
et al., 2001). Sirtinol is a much weaker inhibitor of human
SIRT1 (IC50 of 131 mM), but p-sirtinol inhibited SIRT1
with an IC50 of 13 mM (Mai et al., 2005).
Structure of the SIRT5-ADP Ribose Complex
To determine the structural and molecular mechanisms of
how suramin inhibits sirtuin function, we aimed to obtain
two crystal structures of SIRT5, one in complex with
NAD+, the other bound to the sirtuin inhibitor suramin.
First, we cocrystallized SIRT5 with b-NAD+. In the resulting
structure, however, we only observed the electron density
of ADP-ribose, and not the nicotinamide ring (Figure 2).
ADP-ribose instead of NAD+ was also seen in other sirtuin
crystal structures such as Sir2-Af1 (Min et al., 2001; Chang
et al., 2002). In these structures, the nicotinamide is either
disordered or the N-glycosidic bond between nicotin-
amide and ribose has been hydrolyzed. In one crystal
structure of Sir2-Af1, the flexible loop connecting the
two domains adopted an open form, and the ADP-ribose
ring had C30 endo puckering, suggesting the nicotinamide
ring was disordered (Min et al., 2001). In another structure
of Sir2-Af1, however, the ADP-ribose ring adopted the
C20 exo conformation, and, due to a more closed confor-
mation of the flexible loop (the hydroxyl group linked to C10
of nicotinamide ribose is tightly packed by the surrounding
residues), there was insufficient space to accommodate
the nicotinamide ring, suggesting that b-NAD+ was hydro-
lyzed to ADP-ribose during crystallization (Chang et al.,
2002). In keeping with this hypothesis, although the b-
form of NAD+ was used for cocrystallization, the bound li-
gand was found in an a-form (Chang et al., 2002). In the
case of the SIRT5-ADP ribose structure, NAD+ is present
in its b-form, the flexible loop is partially disordered, and
the nicotinamide ribose ring adopts a C30-endo conforma-
tion, suggesting that the nicotinamide moiety of NAD+ is
disordered. The extra electron density at the C10 position
of the nicotinamide ribose strongly supports this conclu-
sion (Figure 2B).Structure 15, 37In the crystal structure of human SIRT5 in complex with
ADP-ribose, there are four protein molecules in the asym-
metric unit, each including amino acid residues 36–302,
one zinc ion, one HEPES molecule, and one molecule of
ADP-ribose. The SIRT5 monomer consists of 14 a helices
and 9 b strands organized in two globular domains: a large
Rossmann fold domain, characteristic for NAD+/NADH-
binding proteins, and a smaller domain that is involved in
zinc binding (Figure 2A). The cleft between the two do-
mains of SIRT5 is traversed by several loops. The loop,
which connects the helix a2 of the Rossmann fold domain
and the a3 helix of the zinc-binding domain (hereafter
Figure 2. Structure of Human SIRT5
The ADP-ribose, HEPES, and suramin molecules are represented as
ball-and-stick models colored as per atom type: carbon in pink,
oxygen in red, nitrogen in blue, phosphorous in orange, and sulfur in
yellow. The zinc atoms are shown as a sphere.
(A) Overall structure of theSIRT5-ADP ribosecomplex. The zinc-binding
domain and the Rossmann fold domain are highlighted cyan and green,
respectively. The disordered loop connecting the two domains is
marked as a dotted line. The N terminus of the protein is labeled with NT.
(B) Electron density map for the bound ADP-ribose and HEPES mole-
cules in the active site of SIRT5. The initial Fo  Fc difference electron
density map is contoured at 1s (brown). The side chain of the conserved
His158 is represented as a ball-and-stick model. Hydrogen bonds
are indicated by blue dashed lines, water molecules as blue spheres.
(C) Overall structure of the SIRT5 suramin complex. Two monomers
(orange and blue) are linked by one molecule of suramin.7–389, March 2007 ª2007 Elsevier Ltd All rights reserved 379
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SIRT5 Crystal Structurereferred to as the flexible loop), is partially disordered in
the SIRT5-ADP ribose structure (Figure 2A). The number
of disordered residues varies in the four molecules in the
asymmetric unit, which are otherwise very similar. The
Rossmann fold domain comprises six parallel b strands
(b1–b3 and b7–b9) that form a central b sheet, and nine
a helices (a1, a2, a6, a7, and a10–a14) that pack against
the b sheet. The zinc-binding domain contains a small,
three-stranded antiparallel b sheet (b4, b5, and b6) and
five a helices (a3–a5, a8, and a9) (Figure 2A). A conserved
salt bridge involving the amino acids Arg217 and Glu225
contributes to the positioning of the zinc ribbon motif.
Arg217 is located in b6 of the small domain, and Glu225
lies in the loop region connecting the zinc-binding domain
and the a10 helix of the Rossmann fold domain (Figure 3).
The zinc ion is coordinated in a tetrahedral manner to
Cys166, Cys169, Cys207, and Cys212, amino acid resi-
dues that are conserved within the sirtuin family (Figure 3).
As expected, the overall domain organization and fold
of SIRT5 is similar to other reported sirtuin structures.
The overall structure of SIRT5, a mitochondrial class III
sirtuin that is phylogenetically closest to prokaryotic sir-
tuins, is more similar to bacterial sirtuin crystal structures
(Figure 4). The Ca atoms of the structures of human
SIRT5, E. coli CobB, and SIR2 homolog from Archaeoglo-
bus fulgidus (Sir2-Af1) superimpose with a root-mean-
square deviation of 1.5 A˚ (Zhao et al., 2004a; Min et al.,
2001). The Ca atoms of the structures of human SIRT2
and yeast Hst2 superimpose with root-mean-square devi-
ations of 3.2 A˚ and 4.5 A˚ on human SIRT5, respectively
(Finnin et al., 2001; Zhao et al., 2003a). The catalytic do-
mains of sirtuins superimpose closely. Structural differ-
ences are seen in the variable amino- and carboxy-termi-
nal extensions found in other eukaryotic sirtuins, where
they regulate their subcellular localizations and catalytic
activities (North and Verdin, 2004). In both human SIRT2
and yeast Hst2, for example, an additional C-terminal
a helix is present in the crystal structure, packing against
the Rossmann fold domain; this helix is not found in the
prokaryotic sirtuins Sir2-Af1, Sir2-Af2, Sir2-Tm, and
CobB and is also not present in human SIRT5 (Figure 4).
Another structural difference in the Rossmann fold domain
is seen in helix a13 of SIRT5, which is replaced by a longer
helix and a loop insertion in SIRT2 (Figure 4). The superim-
position shows that those helices are shifted by 8 A˚. The
corresponding helix is also relocated in the yeast Hst2
structure, while in the structures of Sir2-Tm and Sir2-Af1
the helices superimpose closely, but is disordered in the
CobB structure.
Structural differences between SIRT5 and other sirtuin
crystal structures are also observed in the smaller zinc-
binding domain. In human SIRT5 there is a unique inser-
tion comprising helix a9 and the 16 amino acid residue
loop that precedes the helix (Figure 4). The insertion, bear-
ing mostly nonpolar amino acid residues and five charged
amino acid residues (Lys187, Glu191, Asp196, Glu202,
and Lys203), is also found in the amino acid sequence of
human SIRT4, which is, as is SIRT5, located in mitochon-
dria (Michishita et al., 2005) (Figure 3). Furthermore, helix380 Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd All ra8 of SIRT5 zinc-binding domain is replaced by a longer
helix in the structures of SIRT2 and Sir2 from Thermotoga
maritima (Sir2-Tm) (Figure 4). In bacterial CobB, a class III
sirtuin as is SIRT5, the region a8-a9 is missing.
The structural differences between the sirtuins de-
scribed above are seen on the surface of the protein and
thus have a potential role for regulation of protein-protein
interactions and catalytic activity. The unique regions of
sirtuin proteins, such as the insertion in the zinc-binding
domain of SIRT5, may also offer avenues for the develop-
ment of specific inhibitors. In fact, it has been shown that
substrate specificity of sirtuins also derives from regions
outside the sequence local to the acetylated lysine residue
(Zhao et al., 2004a), and that the unique N- and C-terminal
extension of yeast Hst2 play autoregulatory roles in catal-
ysis (Zhao et al., 2003a).
In SIRT5, the unique inserted loop region in the zinc-
binding domain is in close proximity to the flexible loop
(which has a proposed role in the release of the reaction
product) (Figure 2A). The interaction is stabilized by three
hydrogen bonds (Trp77, Arg78, and Ala189) and one salt
bridge (Arg78 and Glu100). The inserted loop region addi-
tionally interacts with the a5 helix (which is involved in
HEPES and suramin binding; Tyr102 and Arg105) of the
zinc-binding domain via a salt bridge between Arg97 and
Asp196, and a hydrogen bond between Glu100 and
Gly188 (Figure 3). Taken together, structural rearrange-
ments occurring in the Rossmann fold domain during ca-
talysis are likely to be translocated to the zinc-binding
domain. Vice versa modulators binding to the zinc-binding
domain, particularly to the inserted region in SIRT5, would
be expected to affect catalysis. Such modulators might be
either small-molecule compounds or interacting protein
partners. Furthermore, it is also possible that some sirtuins
only efficiently deacetylate their specific in vivo substrates
in complex with other proteins. To date, however, only little
is known about human sirtuin function in multiprotein com-
plexes. Human SIRT2, for example, was reported to inter-
act with the homeobox transcription factor HOXA10 (Bae
et al., 2004). SIRT2 additionally was suggested to be
part of a tubulin deacetylating multiprotein complex con-
taining HDAC6 (North et al., 2003); however, a more recent
paper reports that SIRT2 is a histone deacetylase with
a preference for histone H4 Lys16 during mitosis (Vaquero
et al., 2006). The structural basis of sirtuin-protein interac-
tions in multiprotein complexes still remains unclear, and
crystal structures of sirtuins in complex with native full-
sized acetylated substrates still remain to be solved.
The NAD+-binding pocket of sirtuins is generally divided
into three regions (Min et al., 2001). The adenine ribose
moiety of NAD+ is bound in site A, the nicotinamide ribose
moiety is bound in site B, and site C lies deep inside the
pocket and reflects the binding site for nicotinamide (see
also Avalos et al., 2005). ADP-ribose interactions in the
SIRT5 active site are shown in Figures 5A and 6A. A key
interaction in the B-site of the cofactor-binding pocket is
the hydrogen bond of the 30 hydroxyl of the nicotinamide
ribose ring to His158, a residue that is thought to function
as a general base to directly deprotonate the 30 hydroxylights reserved
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SIRT5 Crystal StructureFigure 3. Structure-Based Sequence Alignment of Selected Sirtuins
Amino acid sequences used in the alignment correspond to human SIRT1 through SIRT7 (SIRT1–7_Hs), Sir2-Af2 from Archaeoglobus fulgidus, Hst2
from yeast, and Sir2 from Thermotoga maritima (Sir2_Tm). Secondary structure elements correspond to SIRT5-ADP ribose structure. Coloring is as in
Figure 1: the zinc-binding domain in cyan, the Rossmann fold domain in green. Residues forming hydrogen bonds contributing to the binding of
ADP-ribose (;) and HEPES (:) are indicated above the alignment, and residues involved in zinc (>) and suramin binding ( ) are shown below
the alignment. Residues involved in salt bridges are marked with (D). The disordered loop regions and the insertion in the zinc-binding domain are
highlighted in red.Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd All rights reserved 381
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SIRT5 Crystal StructureFigure 4. Comparison of the SIRT5 Overall Structure with Other Sirtuin Crystal Structures
The crystal structure of SIRT5 (purple) was superimposed on the structure of CobB (blue) (A) and on human SIRT2 (yellow) (B). The unique insertion in
the zinc-binding domain of SIRT5, the flexible loop region connecting the two domains, the structural difference in helices a8 and a13, and the N- and
C-terminal extensions seen in eukaryotic sirtuins are highlighted. The zinc ion is included as a gray sphere.of the ribose ring during catalysis. The 30 hydroxyl of the
nicotinamide ribose ring additionally forms a water-medi-
ated contact to the side chain of Asn141. In the A-site of
the pocket, the adenine ribose ring of ADP-ribose has
a C20-endo puckering and interacts with the side chain
of Asn275. The adenine ring is in the anti conformation
and forms hydrogen bonds to Glu64 and Cys293. Most
of the residues involved in ADP-ribose binding are con-
served within the sirtuin protein family (Figure 3).
Interestingly, the SIRT5-ADP ribose complex structure
also shows a bound HEPES molecule whose sulfonate
group interacts with the side chains of Tyr102 and
Arg105 (Figures 5A and 6A). The HEPES molecule is fur-
ther held in place via a hydrogen bond to the 20 hydroxyl
of the nicotinamide ribose ring and thus stabilizes NAD+
binding. A superimposition of the SIRT5 structure bound
to ADP-ribose and HEPES on the structure of Sir2-Tm
bound to p53 peptide substrate and nicotinamide (Avalos
et al., 2005) shows that the HEPES molecule is located in
the putative binding site of the acetylated lysine of the
peptide substrate (Figure 7B), thus mimicking the ternary
complex structure.
Structure of the SIRT5-Suramin Complex
It was predicted that sirtuin inhibitors compete either for
the NAD+-binding site or bind to the acetyl-lysine peptide
site, or to unknown allosteric sites on the enzyme, thereby
altering catalytic activity (Grubisha et al., 2005). A general
inhibitor of sirtuins is its reaction product nicotinamide
(Bitterman et al., 2002; Jackson et al., 2003; Landry
et al., 2000; Sauve and Schramm, 2003). The structural
basis of inhibitory nicotinamide binding has previously382 Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd Allbeen described. Nicotinamide inhibits deacetylation by
binding to the C-pocket, and promoting a base-exchange
reaction at the expense of deacetylation (Avalos et al.,
2005). Hereinafter we describe the structural basis of
SIRT5 inhibition by suramin.
The crystal structure of SIRT5 bound to suramin con-
tains one dimer per asymmetric unit. Within the dimer,
two monomers are linked by one molecule of suramin
(Figure 2C). SIRT5, which is a monomer in solution, also
dimerizes in solution upon suramin binding, as confirmed
by size-exclusion chromatography (data not shown). In
the crystal structure, the monomer-monomer interface is
relatively small, with a buried accessible surface area of
400 A˚2 (3.3% of the accessible surface area). The interface
is mostly nonpolar and there are no direct hydrogen bonds
between the two monomers; however, two bridging water
molecules mediate interactions within the dimer. The
dimeric structure of SIRT5 is mainly stabilized by the
bound suramin itself.
The overall fold of the monomer in the structure of SIRT5
bound to suramin is similar to that seen in the SIRT5 crystal
structure bound to ADP-ribose. A superimposition leads to
a root-mean-square deviation between the Ca atoms of
0.53 A˚. However, in the suramin-bound structure, signifi-
cant structural changes are observed within the flexible
loop connecting the Rossmann fold domain and the zinc-
binding domain. While this loop is partially disordered in
the SIRT5-ADP ribose structure, it is ordered and has a dif-
ferent conformation in the structure of SIRT5 bound to sur-
amin (Figure 7A). The flexible loop forms the back wall of
the putative nicotinamide-binding site in the C-pocket
and bears the amino acid residues Phe70 and Arg71,rights reserved
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SIRT5 Crystal StructureFigure 5. Schematic Illustration of the
ADP-Ribose and Suramin-Binding Sites
Hydrogen bonds are indicated as dashed lines,
water molecules as spheres.
(A) Protein residues involved in ADP-ribose and
HEPES binding. Residues from the zinc-bind-
ing and Rossmann domain are marked in
cyan and green, respectively. Red highlighted
residues are located in the flexible loop region.
(B) Protein residues involved in suramin bind-
ing. Residues from chains A and B are shown
in orange and blue, respectively.which directly interact with suramin (Figure 6B). These
findings explain why that loop becomes ordered in the sur-
amin complex structure and support the role for the loop in
the release of the reaction product nicotinamide, as previ-
ously proposed for yeast Hst2 and Sir2-Af2 (Zhao et al.,
2004b; Avalos et al., 2005). Another structural change in
the SIRT5-suramin structure is seen in a C-terminal region
situated near the putative adenine ribose moiety, reflecting
site A of the NAD+-binding pocket. This region (connecting
b8 and b9) is disordered in the SIRT5 structure bound to
suramin, while it is ordered and includes helix a13 in the
SIRT5-ADP ribose structure (Figure 7A). As seen in Fig-
ure 6, this region is stabilized upon NAD+ binding. Particu-
larly, amino acid Asn275, which is located immediate to
a13, interacts with the adenine ribose ring of the cofactor.
Figures 5B and 6B give a detailed illustration of suramin
contacts in the SIRT5 active site. The sulfonate groups ofStructure 15, 37suramin mediate the majority of the interactions to the pro-
tein and are bound to the core domain of the protein
through hydrogen bonds involving side chains of amino
acid residues Tyr102, Arg105, Arg71, Arg141, and the
main chain of Phe70. Interestingly, two of those residues
listed above, namely Tyr102 and Arg105, are also involved
in the binding the sulfonate group of the HEPES molecule
seen in the SIRT5-ADP ribose structure. The carbonyl
oxygen of the carbonylimino group linking the naphtha-
lene ring and the benzene ring of suramin is hydrogen
bonded to His158, thus mimicking the interaction of the
30 hydroxyl group of the nicotinamide nucleoside of
NAD+ in the B-pocket (Figure 6B). The superimposition
of the SIRT5-ADP ribose and the SIRT5-suramin complex
structure clearly shows that suramin occupies the binding
site of the nicotinamide ribose of the cofactor (Figure 7A).
Furthermore, the superimposition illustrates the different7–389, March 2007 ª2007 Elsevier Ltd All rights reserved 383
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SIRT5 Crystal StructureFigure 6. Stereo Diagram of ADP-Ribose
and Suramin in the SIRT5 Active Site
Active site residues that make contact with
ADP-ribose (A) and suramin (B) are shown as
ball-and-stick models. Water molecules are
shown as blue spheres. Both panels have the
same orientation.conformation of helix a11 and its preceding loop that is
shifted by 5.3 A˚ upon suramin binding, facilitating access
of the inhibitor to the active site (Figure 7A). The shifted
region bears the amino acid Tyr255, whose side chain is
hydrogen bonded to the urea carbonyl oxygen in the cen-
ter of the symmetric suramin molecule. We suggest a role
for this region in substrate binding, which is consistent
with the finding that in the crystal structures of CobB
bound to H4 peptide and Sir2-Tm bound to p53 peptide,
the loop region following the helix is folded into a b strand,
making b sheet interactions with the peptide substrate
(Zhao et al., 2004a; Avalos et al., 2002).
To compare suramin binding with substrate and product
binding, we superimposed the SIRT5-suramin structure
with the structure of Sir2-Tm complexed with p53 peptide
and nicotinamide (Avalos et al., 2005). Figure 7C illustrates
that one sulfonyl group of suramin binds into the C-pocket
and occupies the site where nicotinamide, a general inhib-
itor of all sirtuins, binds in the ternary complex. Moreover,
we show that suramin occupies the peptide substrate-
binding site and binds to a region distinct from the acety-
lated lysine residue. Suramin occupies the site where the
second residue C-terminal to the acetyllysine (position +2)
is located, a site that has been shown to play a significant
role in sirtuin substrate binding (Cosgrove et al., 2006).
Taken together, we show that suramin inhibits SIRT5 activ-
ity by mimicking the contacts of the nicotinamide ribose of
the cofactor in the B-pocket (His158), the reaction product
nicotinamide in the C-pocket (Phe70), and the peptide in
the substrate-binding site (Tyr255).384 Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd All rImplications for Further Developments of Sirtuin
Inhibitors
Both in the crystal structure as well as in solution, suramin
acts as a linker molecule resulting in dimerization of SIRT5.
The simultaneous binding of one molecule of suramin at
the surfaces of two monomers was also seen in the struc-
ture of the suramin-myotoxin II complex (Murakami et al.,
2005). For sirtuins, however, this finding might introduce
a new class of inhibitors that not only bind specifically
into the active site but also function as linker molecules,
thus limiting enzyme mobility and accessibility.
Its large, flexible, and chemically multifunctional nature
causes suramin to be a nonselective sirtuin drug. The
fact that suramin also targets the NAD+-binding pocket
of SIRT5 may make it nonselective for similar binding
pockets. Indeed, suramin has been reported to inhibit
various other NAD+/NADP+-dependent enzymes such as
the lactate dehydrogenase from Dirofilaria immitis and
Onchocerca volvulus, glyceraldehyde-3-phosphate dehy-
drogenase from Trypanosoma brucei, and rat steroid 5
alpha-reductase (Walter, 1979; Walter and Schulz-Key,
1980; Lambeir et al., 1991; Taylor et al., 1995). One may
hypothesize that the development of selective sirtuin
inhibitors may require the preferential targeting of the
acetylated peptide substrate-binding site and not the
NAD+-binding pocket, in order to avoid binding to other
NAD+-consuming enzymes such as various cellular dehy-
drogenases. However, we suggest that the development
of highly specific sirtuin inhibitors rather may be achieved
by targeting both the NAD+ and the substrate-binding sitesights reserved
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SIRT5 Crystal StructureFigure 7. Stereo Diagram of the Super-
imposition of the SIRT5 Structures
(A–C) (A) The structure of SIRT5 in complex
with ADP-ribose and suramin were superim-
posed. Structural differences seen in the
flexible loop, helix a11 and helix a13 are high-
lighted. In (B) a superimposition of the SIRT5-
ADP ribose structure and the structure of
Sir2-Tm complexed with p53 peptide and nic-
otinamide (1YC5; shown in brown) is shown.
(C) To compare suramin binding with peptide
substrate and product binding, the SIRT5-
suramin structure was superimposed on the
structure of Sir2-Tm complexed with p53 pep-
tide and nicotinamide (1YC5; shown in brown).
In (B) and (C) the cartoon model corresponds to
the SIRT5-suramin complex structure. ADP-
ribose, HEPES, and suramin are shown as
ball-and-stick models. All panels in this figure
have the same orientation as in Figure 6.as seen in our SIRT5-suramin complex structure. One
would need to overcome the nonselectivity of suramin
that is due to its chemically multifunctional nature and
evidenced by its alternate binding modes to several other
proteins (Murakami et al., 2005). The trisulfonyl naphthyl
group of suramin, however, and adjacent moieties may
serve as a model for the development of new selective
sirtuin inhibitors.
Conclusions
We purified bacterially expressed human sirtuin SIRT5
and showed that it has NAD+-dependent deacetylase
activity, which can be inhibited by suramin. To provide
insights into the structural basis of sirtuin inhibitor
binding, we determined two crystal structures of human
SIRT5, one in complex with ADP-ribose, the otherStructure 15, 37bound to suramin. We showed that suramin inhibits sir-
tuin activity by binding into the B- and C-pockets of the
NAD+-binding site as well as to the substrate-binding
site. Finally, our structural studies provide, to our knowl-
edge, the first view of a synthetic inhibitory compound
in a sirtuin active site and may enable the rational de-
sign of more potent inhibitors with potential therapeutic
applications.
EXPERIMENTAL PROCEDURES
Abbreviations
Abbreviations used in this article include: sirtuin, SIRT; adenosine-5-
diphosphate ribose, ADP-ribose; nicotinamide adenine dinucleotide,
NAD+; Sir2 from Thermotoga maritima, Sir2-Tm; Sir2 proteins from
Archaeoglobus fulgidus, Sir2-Af1 and Sir2-Af2.7–389, March 2007 ª2007 Elsevier Ltd All rights reserved 385
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SIRT5 Crystal StructureTable 1. Data Collection and Refinement Statistics
SIRT5-ADP Ribose Complex SIRT5-Suramin Complex
Space group P1 P21 (P1 21 1)
Cell dimensions: a, b, c (A˚) 44.57, 58.76, 104.96 41.20, 116.21, 55.99
93.50, 92.75, 94.98 90.00, 90.46, 90.00
Resolution (A˚) 40.301.90 58.122.06
Total number of reflections 154,229 52,783
Unique reflections 79,819 28,096
Completeness (%) 96.1 (85.1)a 86.4 (86.5)
I/s (I) 7.1 (1.6) 11.9 (2.0)
Rmerge (%) 8.1 (35.3) 5.3 (36.5)
Rcryst. (%) 0.185 0.202
Rfree (%) 0.236 0.269
Number of protein atoms 8,018 3,948
Number of nonprotein molecules
ADP-ribose 4 —
Zinc 4 2
HEPES 4 —
Suramin — 1
Water 711 259
Root-mean-square bond lengths (A˚) 0.019 0.008
Root-mean-square bond angles () 1.822 1.730
B factors (A˚2)
Overall 25.68 21.64
Protein 24.9 21.1
ADP-ribose/HEPES 30.5 —
Zinc 21.6 27.1
Suramin — 24.1
Solvent 31.8 28.4
Ramachandran Plot
Percentage of nonglycine residues
Most favored regions 90.8 90.9
Additional allowed regions 8.6 7.7
Generously allowed regions 0.7 0.2
Disallowed regions — 0.2 (Arg78)
a Numbers in parentheses are for the highest resolution shell. For structural analyses and comparison of the SIRT5 crystal structure
bound to ADP-ribose, chain C was chosen, since it contains two more amino acid residues in the disordered flexible loop, and
because it has the lowest B factors for bound molecules ADP-ribose and HEPES.Materials
Thrombin and b-NAD+ were obtained from Sigma-Aldrich, and sura-
min was obtained from Biomol International LP. All other chemicals
were of the highest purity available.
Protein Cloning, Expression, and Purification
Alternative splicing of the SIRT5 gene results in two transcription var-
iants. The SIRT5 isoform 1 was amplified by PCR from the Mammalian
Gene Collection clone (accession code gi:6912664) and was subcl-386 Structure 15, 377–389, March 2007 ª2007 Elsevier Ltd Alloned into a modified pET28a-LIC vector. The recombinant protein
(amino acids 34–302) was overexpressed as an N-terminal His6-
tagged protein using E. coli BL21 (DE3) Codon plus RIL (Stratagene)
as a host organism. For purification, cells were lysed by passing
through Microfluidizer (Microfluidics Corporation) at 18,000 psi. The
purification procedure comprises three chromatographically steps:
(1) an affinity chromatography on a 5 ml HiTrap Chelating column
(Amersham Biosciences), charged with Ni2+, (2) a size-exclusion
chromatography on a Superdex 200 column (26 3 60, Amershamrights reserved
Structure
SIRT5 Crystal StructureBiosciences), and (3) a cation-exchange chromatography on a Source
30S column (10 3 10, Amersham Biosciences). The his tag was
cleaved with thrombin after gel filtration step.
Protein Crystallization
Purified SIRT5 was crystallized using the hanging drop vapor-diffusion
method at 20C by mixing 1.5 ml of the protein solution with 1.5 ml of the
reservoir solution. The complexes were prepared as follows: 10 mg/ml
SIRT5 solution was directly complexed with b-NAD+ at 1:20 molar ratio
of protein to NAD+. To obtain the SIRT5-suramin complex, suramin
was added at a 5-fold molar excess to diluted protein solution,
followed by coconcentration up to 10 mg/ml. Crystals for SIRT5 com-
plexed with NAD+ were grown in a condition containing 18% PEG
4000, 0.1 M HEPES-NaOH (pH 7.5), and 10% isopropanol, and crys-
tals for the SIRT5 bound to suramin in 25% PEG 3350, 0.1 M BIS-
TRIS (pH 6.5), and 0.2 M NaCl. Before flash-freezing the crystal in liquid
nitrogen, the crystal was soaked in a cryoprotectant consisting of
80% reservoir solution and 20% glycerol.
Data Collection and Processing
X-ray diffraction data for SIRT5 bound to ADP-ribose were collected
at beamline X12C of National Synchrotron Light Source (NSLS) at
Brookhaven National Laboratory (BNL). Diffraction data for SIRT5 in
complex with suramin were collected at 100 K on a FR-E/R axis
IV++ diffraction system (Rigaku/MSC) using Cu radiation. X-ray data
were measured at wavelength 0.9797 A˚ (2B4Y) or 1.54 A˚ (2NYR), re-
spectively, and processed using the programs HKL2000 (2B4Y), DENZO
(2NYR), and SCALEPACK (Otwinowski and Minor, 1997). Data statistics
are reported in Table 1.
Structure Determination and Refinement
The structures of both of the SIRT5 complexes were solved by molec-
ular replacement using the program PHASER (McCoy et al., 2005). The
model of the Sir2 homolog Sir2-Af1 (PDB ID 1ICI) (Min et al., 2001)
served as a template. Refinement of the model was performed with
REFMAC (Murshudov et al., 1997). The graphic program COOT was
used for model building and visualization (Emsley and Cowtan,
2004). Statistics on structure refinement are summarized in Table 1.
Structural Analysis
Structure comparisons were carried out using the program PYMOL
(DeLano, 2002). Sequence alignments were performed with ClustalW
(Thompson et al., 1994). Figures were created with PYMOL (DeLano,
2002).
Aggregation-Based Screening Using Static Light Scattering
Temperature-dependent aggregation was measured using static light
scattering (StarGazer, Affinium Pharmaceutical) (Vedadi et al., 2006).
50 ml of protein (0.4 mg/ml) was heated from 27 to 80C at a rate of
1C per min in each well of a clear-bottom 384-well plate (Nunc).
Protein aggregation was monitored by measuring the intensity of the
scattered light every 30 s with a CCD camera. The pixel intensities in
a preselected region of each well were integrated to generate a value
representative of the total amount of scattered light in that region.
These total intensities were then plotted against temperature for
each sample well and fitted to the Boltzman equation by nonlinear
regression. The resulting point of inflection of each resulting curve
was defined as the temperature of aggregation, Tagg. The Tagg was de-
termined in the presence and absence of different compounds. Ligand
binding was detected by monitoring the increase in Tagg in the pres-
ence of the ligand. Intensities were plotted as a function of temperature
using a software package developed internally.
Isothermal Titration Calorimetry
Isothermal titration calorimetry measurements were performed in
duplicate at 25C using a VP-ITC microcalorimeter (MicroCal Inc.). In
an experiment 10 ml suramin solution (1.1 mM) was injected into the
sample cell containing 100 mM of SIRT5 solution. A total of 25 injec-Structure 15, 37tions were performed with a spacing of 180 s and a reference power
of 15 mCal/s. Binding isotherms were plotted and analyzed using Origin
Software (MicroCal Inc.)
Enzymatic Assays
The NAD+-nicotinamide exchange activity assay in the presence of an
acetylated substrate (BSA) was done as described by Landry and
Sternglanz (2003). Enzyme plus either BSA or acetylated BSA
(0.5 mg/ml) was incubated with radioactive nicotinamide. Enzyme con-
centrations were 200 ng yeast Sir2 and 200, 400, or 600 ng SIRT5. The
concentration of NAD+ was 0.5 mM. To test NAD+-dependent SIRT5
deacetylase activity, the NAD+ hydrolysis assay described by Landry
and Sternglanz (2003) was applied. The concentration of SIRT5 was
200, 400, and 600 ng. 1 mCi of 3H-NAD+ (20 mM) and 0.5 mg/ml BSA
or acetylated BSA, and 0.25 mg/ml acetylated histone peptide were
used. As histone substrates, chemically acetylated chicken histone
and monoacetylated H4 (K5, K8, K12, or K16) were tested. The IC50
value of SIRT5 inhibition by suramin was measured using acetylated
chicken histone as substrate. The suramin concentration was varied
between 0 and 100 mM. The reaction volume of the assays was 20 ml.
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